Delivery Order SPE2DB20D2104-SPE2DB25FMWUF
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 26, 2025, for the supply of SKYRIZI 180 mg/1.2 mL on-body injectors valued at $11,830.00. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award based on open competition. The contract will be completed by August 15, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic...
- The Defense Logistics Agency awarded a $11,830.00 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 180 mg/1.2 ml on-body injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price contract represents a competitively awarded, non-set-aside procurement of the pharmaceutical product to support federal medical supply requirements. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of SKYRIZI 360 mg/2.4 mL on-body injectors valued at $11,830.00 under a firm fixed price contract. The order, which is expected to be completed by September 9, 2025, will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded without a set-aside designation, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 mL on-body injectors on July 25, 2025. This firm fixed-price delivery order is scheduled for completion by August 15, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The award utilized no set-aside designation and was competitively awarded. SKYRIZI is a biologic medication used to treat autoimmune conditions, and this...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $11,830.00 for SKYRIZI 360 mg/2.4 mL on-body injectors on July 23, 2025, with completion expected by August 13, 2025. The contract employs firm fixed pricing with no set-aside designation and represents a competitively awarded transaction. Performance will take place at the vendor's Conshohocken facility. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 ml on-body injector devices. This firm fixed price delivery order, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a competitive award with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and falls under the company's...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 mL on-body injectable medication. This firm fixed-price, non-set-aside contract was awarded on July 28, 2025, with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 mL on-body injectors. This firm fixed price, non-competitive delivery order was issued on August 8, 2025, with an ultimate completion date of August 29, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injectors, valued at $13,637.01 under a firm fixed price contract. The award, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a non-set-aside competitive procurement. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 mL on-body injection units, valued at $11.8K with a firm fixed price structure. This is a non-set-aside competitive award issued on August 13, 2025, with an ultimate completion date of September 4, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. SKYRIZI is a prescription biologic medication indicated for the treatment of...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMWUFDelivery Order
The Defense Logistics Agency awarded a $11,830 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 MG/2.4 ML on-body injector units on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order, which was competitively awarded with no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a prescription biologic medication used to treat autoimmune conditions, and this delivery order represents a specific requisition under a larger contract vehicle. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract with the DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical prime vendor contract running through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio of federal medical supply contracts demonstrates its capability to fulfill diverse pharmaceutical and medical device requirements through open competition, supporting military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 7/29/25 |